INIS
patients
100%
diseases
61%
ischemia
60%
biological markers
60%
risks
54%
levels
45%
thrombosis
41%
design
39%
comparative evaluations
32%
males
30%
people
30%
communities
30%
clinical trials
30%
esterases
30%
reviews
30%
medicine
30%
netherlands
30%
hospitals
22%
glycoproteins
22%
enzyme inhibitors
20%
volume
20%
data
19%
interactions
17%
performance
12%
accuracy
12%
tools
12%
bridges
11%
fibrinogen
10%
size
10%
vessels
10%
modifications
10%
plasma
10%
mortality
10%
enzymes
10%
administration
10%
implementation
8%
adults
7%
antibodies
7%
control
7%
detection
6%
assessments
6%
diagnosis
6%
evaluation
6%
sensitivity
6%
specificity
6%
guidelines
6%
tissues
5%
plasminogen
5%
hemostatics
5%
Keyphrases
Endovascular Treatment
55%
Acute Ischemic Stroke Patients
38%
Acute Ischemic Stroke
32%
Clinical Outcomes
32%
Community-dwelling
30%
Frail Elderly
30%
Thrombectomy
30%
Endovascular Thrombectomy
30%
Risk Factors
30%
Pre-frail
30%
Odds Ratio
30%
Hospitalization
30%
Primary Hemostasis
30%
Secondary Hemostasis
30%
Ischemic Stroke Outcome
30%
Coagulation Activity
30%
Antithrombin
30%
Imaging Results
30%
Netherlands
30%
Von Willebrand Factor
30%
Multicenter Randomized Clinical Trial
30%
Antiphospholipid Syndrome
30%
Intravenous Thrombolysis
27%
Informal Care
12%
Self-perceived Health
12%
Modified Rankin Scale
10%
Male Gender
9%
Hospital Admission
9%
Frailty
9%
Thrombosis
8%
Factor Level
8%
Platelets
8%
Glycoprotein VI
7%
C1 Esterase Inhibitor
7%
Coagulation Activation
7%
Treatment Group
7%
Chronic Disease
6%
Multivariable Logistic Regression
6%
Pre-frailty
6%
Target Disorder
6%
Frontline Physicians
6%
Measurements Integration
6%
Measurement Interpretation
6%
Autoimmune Disease
5%
Autoantibodies
5%
β2-glycoprotein I (β2GPI)
5%
Final Infarct Size
5%
National Institutes of Health Stroke Scale (NIHSS)
5%
Fibrinogen
5%
Thrombolysis in Cerebral Infarction
5%
FVIIa
5%
Final Infarct Volume
5%
FIXa
5%
Volume-outcome
5%
Enzyme-inhibitor Complex
5%
FXIIa
5%
FXIa
5%
Disintegrin
5%
Metalloprotease
5%
Thrombospondin-1 (TSP-1)
5%
Treatment Effect
5%
Medicine and Dentistry
Venous Thromboembolism
39%
Thrombosis
38%
Odds Ratio
30%
Biological Marker
30%
Diagnostic Test
30%
Meta-Analysis
30%
Systematic Review
30%
Von Willebrand Factor
30%
Translational Medicine
30%
Antiphospholipid Syndrome
30%
Frailty
18%
Disease
12%
Diagnostic Accuracy
12%
Platelet
8%
Logistic Regression Analysis
6%
Chronic Disease
6%
False Positive Result
6%
Sensitivity and Specificity
6%
False Negative Result
6%
Diagnostic Performance
6%
Thromboembolism
6%
Autoantibodies
5%
Isoetarine
5%
Autoimmune Disease
5%
Beta2 Glycoprotein 1
5%